Skip to content
Search

Latest Stories

RPS seeks evidence on Pharmacy-medicine self-selection over the next 3 months

RPS seeks evidence on Pharmacy-medicine self-selection over the next 3 months
Previously at odds with GPhC over facilitated self-selection of Pharmacy medicines, RPS urges comprehensive evidence  amidst widening practice in pharmacies

In light of the recent change facilitated by the General Pharmaceutical Council (GPhC) to allow more pharmacies to adopt facilitated self-selection of Pharmacy (P) medicines, the Royal Pharmaceutical Society (RPS) has launched a call for evidence.

The pharmacy body has opened a consultation on facilitated self-selection of P-meds for submissions from July 12 to September 6, 2024.


They are seeking views and opinions from a diverse group, including pharmacists, pharmacy teams, patient representatives, employers, academics, think tanks, pharmacy bodies, regulators, and researchers.

The initiative stems from the RPS National Pharmacy Boards meeting in June, which scrutinised the Society’s current stance against self-selection, as outlined in the RPS guide "Medicines, Ethics and Practice."

The RPS is now seeking comprehensive evidence on the benefits and potential harms of this model, focusing on patient care and identifying any gaps that require further research.

RPS Chief Executive Officer, Paul Bennett commented, "Following changes brought by the GPhC focusing on an outcomes approach to standards, they have confirmed they no longer prohibit facilitated self-selection of P medicines.

"As a result, there are pharmacies that are now adopting a more flexible interpretation to providing this group of medicines.

"The GPhC have stated that sale and supply of a P medicine must still take place in a registered pharmacy premises under the supervision of a pharmacist, and that appropriate measures should be in place to ensure that supervision continues.

Bennett emphasised that the evidence collected will shape an RPS report aimed at re-evaluating their current position.

"As the professional body, we are committed to patient safety and the safe development of innovative practice to meet the needs of patients now and for the future.

"Please share the call for evidence with your networks," he added.

Insights from Community Pharmacist

"Once the genie is out of the bottle, standards will quickly erode due to a lack of effective policing," warned Gursaran Singh Matharu (Raj), Chief Executive Officer of Community Pharmacy South East London, about the impact of self-selection on patient safety and professional care.

He told Pharmacy Business that the decision to place P-medicines near the dispensary "is a strategic decision aimed at enhancing patient safety and ensuring pharmacists can oversee and intervene in conversations between staff and pharmacy users when necessary".

"This proximity allows pharmacists to monitor interactions, provide immediate advice, and address any potential issues swiftly, ensuring that patient care remains the top priority," Matharu explained.

He also noted that Integrated Care Boards (ICBs) are reviewing prescribing practices and the overuse of medicines to improve patient safety.

"Overprescribing not only poses a risk to patient health through potential side effects and drug interactions but also contributes to the alarming amount of medical waste, estimated to cost £300 million annually," he said.

Matharu pointed out that pharmacists are handling an increased number of queries from pharmacy users, a trend expected to continue as stricter prescribing practices are implemented.

"This additional workload could strain the capacity of pharmacists, who must balance their advisory role with their dispensing duties," he commented.

However, he emphasised that the system's design, which places pharmacists in a central, accessible location, helps mitigate some of this burden by facilitating efficient communication and intervention.

Furthermore, Matharu highlighted key issues facing the pharmacy sector.

He stated that "the current funding model for community pharmacies is inadequate, leading to staffing shortages, reduced services, and increased pressure on pharmacists, which compromises patient care."

He empahsised that the RPS should lead discussions on improving safety and working conditions for pharmacists.

"High workloads, long hours, and stress are causing burnout and errors, jeopardizing both pharmacist well-being and patient safety.

"The RPS must address how to make primary care delivery in community pharmacies safer and more manageable," he stated.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less